Acarbose
Pegvisomant may increase the hypoglycemic activities of Acarbose.
Albiglutide
Pegvisomant may increase the hypoglycemic activities of Albiglutide.
Alfentanil
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.
Advertisement
Alogliptin
Pegvisomant may increase the hypoglycemic activities of Alogliptin.
Alphaprodine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphaprodine.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Pegvisomant.
Advertisement
Asunaprevir
The serum concentration of Asunaprevir can be decreased when it is combined with Pegvisomant.
Bromocriptine
Pegvisomant may increase the hypoglycemic activities of Bromocriptine.
Buprenorphine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.
Advertisement
Butorphanol
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.
Canagliflozin
Pegvisomant may increase the hypoglycemic activities of Canagliflozin.
Canagliflozin Anhydrous
Pegvisomant may increase the hypoglycemic activities of Canagliflozin.
Chlorpropamide
Pegvisomant may increase the hypoglycemic activities of Chlorpropamide.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Pegvisomant.
Codeine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.
Codeine Anhydrous
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.
CODEINE POLISTIREX
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.
Dapagliflozin
Pegvisomant may increase the hypoglycemic activities of Dapagliflozin.
Dextromoramide
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.
Dezocine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.
Dihydrocodeine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.
Diphenoxylate
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.
Disopyramide
Pegvisomant may increase the hypoglycemic activities of Disopyramide.
Dulaglutide
Pegvisomant may increase the hypoglycemic activities of Dulaglutide.
Empagliflozin
Pegvisomant may increase the hypoglycemic activities of Empagliflozin.
Ethylmorphine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.
Exenatide
Pegvisomant may increase the hypoglycemic activities of Exenatide.
Fentanyl
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.
Gliclazide
Pegvisomant may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Pegvisomant may increase the hypoglycemic activities of Glimepiride.
Glipizide
Pegvisomant may increase the hypoglycemic activities of Glipizide.
Glyburide
Pegvisomant may increase the hypoglycemic activities of Glyburide.
Heroin
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Heroin.
Hydrocodone
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.
HYDROCODONE POLISTIREX
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.
Hydromorphone
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.
Insulin Detemir
Pegvisomant may increase the hypoglycemic activities of Insulin Detemir.
Insulin Glargine
Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.
insulin human, rDNA origin
Pegvisomant may increase the hypoglycemic activities of Insulin Human.
Insulin Lispro
Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Aspart Protamine, Human
Pegvisomant may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Aspart, Human
Pegvisomant may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Glulisine, Human
Pegvisomant may increase the hypoglycemic activities of Insulin Glulisine.
Insulin, Protamine Lispro, Human
Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.
Lanreotide
The risk or severity of adverse effects can be increased when Lanreotide is combined with Pegvisomant.
Levomethadyl
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levomethadyl Acetate.
Levorphanol
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.
Liraglutide
Pegvisomant may increase the hypoglycemic activities of Liraglutide.
Mecasermin
Pegvisomant may increase the hypoglycemic activities of Mecasermin.
Mecasermin Rinfabate
Pegvisomant may increase the hypoglycemic activities of Mecasermin.
Meperidine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pethidine.
Metformin
Pegvisomant may increase the hypoglycemic activities of Metformin.
Methadone
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.
Methadyl Acetate
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl Acetate.
Mifepristone
Pegvisomant may increase the hypoglycemic activities of Mifepristone.
Miglitol
Pegvisomant may increase the hypoglycemic activities of Miglitol.
Morphine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.
Nalbuphine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.
Nateglinide
Pegvisomant may increase the hypoglycemic activities of Nateglinide.
Normethadone
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.
Octreotide
The risk or severity of adverse effects can be increased when Octreotide is combined with Pegvisomant.
Opium
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.
Oxycodone
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.
Oxymorphone
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.
Paregoric
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.
Pasireotide
The risk or severity of adverse effects can be increased when Pasireotide is combined with Pegvisomant.
Pegloticase
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegloticase.
Pentamidine
Pegvisomant may increase the hypoglycemic activities of Pentamidine.
Pentazocine
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.
Pioglitazone
Pegvisomant may increase the hypoglycemic activities of Pioglitazone.
Pirinitramide
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Piritramide.
Pramlintide
Pegvisomant may increase the hypoglycemic activities of Pramlintide.
Propoxyphene
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.
Quinine
Pegvisomant may increase the hypoglycemic activities of Quinine.
Regular Insulin, Human
Pegvisomant may increase the hypoglycemic activities of Insulin Human.
Remifentanil
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.
Repaglinide
Pegvisomant may increase the hypoglycemic activities of Repaglinide.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Pegvisomant.
Rosiglitazone
Pegvisomant may increase the hypoglycemic activities of Rosiglitazone.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Pegvisomant.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Pegvisomant.
Sitagliptin
Pegvisomant may increase the hypoglycemic activities of Sitagliptin.
Sitagliptin Phosphate
Pegvisomant may increase the hypoglycemic activities of Sitagliptin.
Somatostatin
The risk or severity of adverse effects can be increased when Somatostatin is combined with Pegvisomant.
Sufentanil
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.
Sulfadiazine
Pegvisomant may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
Pegvisomant may increase the hypoglycemic activities of Sulfamethoxazole.
Sulfisoxazole
Pegvisomant may increase the hypoglycemic activities of Sulfisoxazole.
Sunitinib
Pegvisomant may increase the hypoglycemic activities of Sunitinib.
Tapentadol
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.
Tolazamide
Pegvisomant may increase the hypoglycemic activities of Tolazamide.
Tolbutamide
Pegvisomant may increase the hypoglycemic activities of Tolbutamide.
Tramadol
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tramadol.
